<DOC>
	<DOCNO>NCT00000887</DOCNO>
	<brief_summary>The purpose study see give nelfinavir ( NFV ) plus zidovudine ( ZDV ) plus lamivudine ( 3TC ) HIV-positive pregnant woman baby safe . This study also look long drug stay blood . ZDV give mother past reduce chance pass HIV baby . However , good treatment need reduce chance good suit treatment need mother child . Taking combination anti-HIV drug pregnancy may answer .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerance Nelfinavir ( NFV ) Given With Zidovudine ( ZDV ) Lamivudine ( 3TC ) HIV-Positive Pregnant Women Their Infants</brief_title>
	<detailed_description>Despite dramatic reduction perinatal HIV transmission administration ZDV mother infant , new potent strategy need reduce perinatal transmission well suit diverse treatment need patient . Initiation triple antiretroviral combination gestation , particularly combination include drug cross placenta 3TC , may effective reduce maternal virus load lowest level prior delivery . Women receive nelfinavir plus 3TC plus ZDV antepartum ( Study Day 0 onset active labor ) postpartum ( cord clamp 12 week ) . [ AS PER AMENDMENT 10/28/97 : If patient present active labor le 1 hour delivery time , institutional protocol ZDV infusion labor follow . ] [ AS PER AMENDMENT 1/26/99 : For maternal dosing , one Combivir tablet bid substitute individual formulation 3TC ZDV . For mother receive Combivir antepartum period , Combivir hold labor delivery , separate formulation ZDV 3TC use . Patients prematurely discontinue study treatment continue follow study duration study . ] Full pharmacokinetic sampling perform 10 15 day start therapy [ AS PER AMENDMENT 2/7/00 : 10 15 day study entry woman currently take nelfinavir ] 5 6 week delivery . A maternal blood sample cord blood sample collect birth analysis nelfinavir concentration . Maternal HIV RNA plasma monitor throughout study . Cervicovaginal secretion collect entry , late gestation , postpartum ass presence HIV . A single pharmacokinetics sample collect cervicovaginal secretion . Serial CD4/CD8 activation marker measure woman gestation postpartum . Infants receive nelfinavir plus 3TC plus ZDV begin approximately 12 hour follow birth continue 6 week . After birth , several blood sample collect infant determination washout kinetics nelfinavir . Full pharmacokinetics sample perform 5 8 day post birth 5 6 week follow multiple dos . Pharmacokinetic sample analyze first six mother-infant pair dose may adjust accordingly next cohort . Agouron agree make nelfinavir available interested study participant period 6 month study via patient assistance program .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are least 13 year old ( need consent parent guardian 18 ) . Are HIVpositive . Are 2nd 3rd trimester ( 14 34 week pregnant ) pregnant one two child . Have normal ultrasound exam . Exclusion Criteria Patients eligible study : Can take ZDV 3TC . Have active opportunistic ( HIVassociated ) bacterial infection , severe medical condition . Have severe diarrhea . Are risk premature birth pregnancy complication . Have family history phenylketonuria ( PKU ) . Plan breastfeed . Abuse alcohol drug . Can visit clinic duration study . Have take certain antiHIV drug .</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Disease Transmission , Vertical</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>